This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Topical Agent for Treatment of Red Skin

This study has been completed.
Information provided by:
Mayo Clinic Identifier:
First received: January 18, 2006
Last updated: May 20, 2011
Last verified: May 2011
SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety

Condition Intervention Phase
Rosacea Bilaterally Symmetric Red Skin on Cheeks Drug: Topical SR-01 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Proof of Concept Trial:SR-01 for the Treatment of Rosacea

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Reduction of redness

Secondary Outcome Measures:
  • Safety and tolerability
  • Cosmetic acceptability

Estimated Enrollment: 20
Study Start Date: July 2005
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Bilaterally symmetric red skin on cheeks Caucasian Age 18-60 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00279890

United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 55259
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Mark V. Dahl, M.D. Mayo Clinic
  More Information

Responsible Party: Mark V. Dahl, M.D., Mayo Clinic Identifier: NCT00279890     History of Changes
Other Study ID Numbers: 44-05
MCS 385
Study First Received: January 18, 2006
Last Updated: May 20, 2011

Additional relevant MeSH terms:
Skin Diseases processed this record on June 23, 2017